跳至主要内容
临床试验/ACTRN12614001014640
ACTRN12614001014640已完成2 期

Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis, a pilot, randomised, controlled trial.

niversity of Tasmania0 个研究点目标入组 30 人开始时间: 2014年9月22日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Entry criteria required a clinical diagnosis of psoriasis involving greater than or equal to 10% of the body surface.

排除标准

  • The main exclusion criteria were current diagnosis of unstable psoriasis, atopic dermatitis and other skin conditions (e.g. seborrhoeic dermatitis, contact dermatitis, cutaneous mycosis, presence of pigmentation, extensive scarring, pigmented lesion) confounding psoriasis assessment, pregnancy, breast-feeding, and use of medications that are known to exacerbate the course of psoriasis (lithium, beta adrenergic blocking agents, antimalarial drugs).
  • Subjects with flexural and pustular psoriasis were not considered because of their rarity and potential treatment difficulties with the trial medications. All patients had a 6-week washout period for systemic therapy (including phototherapy) and 2 weeks for topical psoriatic treatment before receiving the study drugs.

研究者

发起方
niversity of Tasmania

相似试验